When we go to the hospital, the last thing on our mind is that something could go wrong or that we could actually become sicker than when we first went in. Unfortunately, human errors do happen, infections...... (read more)

The latest drug to bite the dust is LY2886721, a beta secretase, or BACE, inhibitor. Eli Lilly stopped a phase 2 trial after some patients had abnormal liver biochemical tests. Companies routinely run...... (read more)

The markets sure lost yesterday's momentum in a hurry. After downbeat economic reports came out this morning, the Dow Jones Industrial Average (INDEXDJX:.DJI) began a day-long sump and has lost more than...... (read more)

With the global economy beginning to stabilize, the stock market is looking more attractive than ever. One industry that could stand to make huge gains in the near future is the pharmaceutical industry...... (read more)

Investing in biotech stocks is relatively risky amid the volatility of the market. There are many factors that can greatly affect share trends and price performance. Biotech companies go through a series...... (read more)

Generic-drug makers are always on the hunt for the next branded drug to take down. But they can't just go about launching copycats of every drug; it's against the law to sell a generic version of a drug...... (read more)

Pfizer Inc. (NYSE:PFE) recently completed the spin-off of its animal health unit, Zoetis Inc (NYSE:ZTS). The company offered to acquire its stake in Zoetis for a 7% discount, in exchange of all or part...... (read more)

Celgene Corporation (NASDAQ:CELG) shares have soared more than 46% so far in 2013. This booming biotech stock can't go much higher, right? Surely, it's time now to take profits. Actually, the company...... (read more)

The back-and-forth trend on Wall Street continued today as markets opened higher only to fall throughout the trading day. There weren't any significant economic releases today, and again traders are citing...... (read more)